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transepithelial electrical resistance; immunosuppressive drugs; nephrotoxicity; claudin CYCLOSPORINE A (CsA) advanced the field of organ transplantation improving allograft survival and quality of life for solidorgan transplant recipients (6, 32) . However, CsA clinical use is limited by adverse effects, the most important of which is nephrotoxicity (4) . CsA nephrotoxicity is characterized by the accumulation of extracellular matrix proteins, tubular necrosis, microangiopathy, interstitial fibrosis, and progressive renal dysfunction (30) . Transforming growth factor (TGF)-␤ has been implicated as a major factor in the development of chronic CsA toxicity. Increased TGF-␤ levels have been observed in renal cells exposed to CsA (11, 33) , in animal models of CsA (26) , and in patients with calcineurin inhibitor nephropathy (23) . Sirolimus (SRL) treatment was introduced as a means to substitute or minimize CsA treatment without loss of immunosuppressive potency. Some studies demonstrated beneficial effects of SRL when used in combination with CsA in both clinical and animal studies (5, 18 -20, 31) . However, other studies indicated that CsA nephrotoxicity was exacerbated with SRL combination (17) . SRL treatment itself has also been shown to increase the production of TGF-␤ in both cell culture and animal models (10, 31, 35) .
Previous studies in our laboratory demonstrated that SRL can have direct effects on the barrier function of renal proximal tubular cells and that these effects are similar to those of CsA (28) . SRL in combination with CsA did not attenuate CsA-induced effects on the barrier function but enhanced these effects in a synergistic manner. Alterations in TGF-␤ levels caused by these immunosuppressive agents may help to explain the effects of these drugs and their combination on paracellular permeability. A number of studies showed that TGF-␤ can alter the barrier function in both epithelial and endothelial cell monolayers. TGF-␤ enhanced the barrier function of T84 intestinal epithelial cells and prevented the disruption of intestinal epithelium caused by different agents as demonstrated by Howe et al. (14) . They showed that TGF-␤ enhanced the barrier function up to threefold as assessed by transepithelial electrical resistance (TER) and that this cytokine was able to prevent the deleterious effect of EHEC (intestinal pathogen enterohemorrhagic Escherichia coli O157:H7) on tight junction (TJ) barrier function. In contrast, TGF-␤ 1 has been shown to prevent glucocorticoid-stimulated TJ formation and reduced TER in murine mammary epithelial cells (36) . Therefore, it is probable that TGF-␤ 1 may produce opposite effects on epithelial barrier function in various tissues.
The intracellular signaling pathways involved in the alteration of the barrier function after TGF-␤ treatment are not fully understood and need to be investigated. There is evidence linking activation of the MAPK pathways to the TGF-␤-induced modulation of TJs and paracellular permeability. Previous work in our laboratory demonstrated that the CsAmediated, TGF-␤-induced increase in TER in Madin-Darby canine kidney (MDCK) II cells involved the activation of the ERK1/2 signaling pathway (11) . The studies by Howe et al. (14) demonstrated similar results in T84 intestinal epithelial cells and showed that the TGF-␤ induced an increase in TER that involved ERK1/2 activation. These authors explored for the first time the implication of the TGF-␤ canonical pathway, the Smad signaling pathway, in the TGF-␤-induced increase in TER. They produced evidence that in T84 cells the TGF-␤-induced effect on TER was not only ERK1/2-depen-dent but also Smad-dependent. The role of the Smad signaling pathway in renal epithelial cells has been explored in terms of induction of epithelial-to-mesenchymal transition but to our knowledge no evidence exists for the implication of this signaling pathway in the TGF-␤ barrier modulation of renal epithelial cells. The present studies were aimed to explore the hypothesis that a CsA/SRL combination may mediate detrimental kidney effects via TGF-␤ and furthermore to elucidate the possible signaling mechanisms involved.
MATERIALS AND METHODS
Cell culture. The renal epithelial cell line LLC-PK1 (from pig proximal tubule) (15) was obtained from the European Collection of Animal Cell Cultures (Wiltshire, UK). Cells were cultured in Medium 199 (GIBCO) supplemented with 10% heat-inactivated fetal calf serum and penicillin/streptomycin (GIBCO). The culture was maintained at 37°C in a humidified incubator gassed with 5% CO 2-95% air. The cells were passaged on a weekly basis (with a split ratio of 1:5).
Cell treatment. CsA and SRL were prepared as stock solutions (4.2 and 1 mM, respectively) in 100% EtOH. TGF-␤ 1 was reconstituted with sterile 4 mM HCl containing 1 mg/ml BSA to a final stock concentration of 5 g/ml. U0126 and SD208 were prepared as stock solutions of 10 mM in DMSO. Neutralizing antibody TGF-␤ 1 (nAb TGF-␤1) was prepared as a stock solution of 500 g/ml by dissolving the powder in PBS. Cells were preincubated for 1 h with 10 M U0126, nAb TGF-␤1 (30 g/ml), or 10 M SD208 before treatment with 4.2 M CsA, 1 M SRL, 4.2 M CsA plus 1 M SRL, or 5 ng/ml TGF-␤1.
TER. LLC-PK1 cells were grown on 24-Costar HTS-Transwell cell culture plates, which consisted of tissue culture-treated polycarbonate membranes with a pore size of 0.4 m and an effective growth area of 0.33 cm 2 . The upper chamber (apical side) contained 0.25 ml medium and the lower one contained 1 ml medium. LLC-PK1 cells were seeded at a density of 2.5 ϫ 10 5 cells/well and the cells were seen to reach a stable TER representing a confluent monolayer 4 days postseeding. Confluent monolayers of cells were treated with various treatments on the apical and on the basolateral side of the filter. The point of addition of the drug was taken as time 0 and TER across the monolayers was monitored over a range of times under sterile conditions in a laminar flow hood using the REMS automated system (World Precision Instruments).
Real-time TaqMan PCR. Gene expression assays were used for porcine TGF-␤ 1. This assay contains the following primers: forward: 5=-CGAGCCAGAGGCGGACTAC-3=, reverse: 5=-TTGCCGCTT-TCCACCATT-3= and FAM dye-labeled TaqMan MGB probe: 5=-FAM-CCAAGGAGGTCACCCGCGTGC-3= TAM. The ribosomal 18S gene was used as an endogenous control for normalization of the target genes. Its primers and probe were supplied as a PDAR (predeveloped assay reagent), part number 4310893E, with the probe labeled with VIC at the 5=-end. PCR reactions were set up in 10-l reactions with TaqMan Universal PCR Master Mix. cDNA was amplified on the ABI 7900HT sequence Detection System at default thermal cycling conditions: 2 min at 50°C, 10 min at 95°C for enzyme activation, and then 40 cycles of 15 s at 95°C for denaturation and 1 min at 60°C for annealing and extension. Results were analyzed using the ⌬Ct method of analysis with normalization for the 18S gene endogenous control.
Immunoprecipitation. Following the appropriate treatment, LLC-PK 1 cells grown on a six-well tissue culture plate were washed twice with ice-cold PBS and then scraped in a radioimmuno-precipitation assay (RIPA) buffer [90% RIPA buffer (Sigma), 10% of 1 mM Na 3VO4, 1% 1 mM PMSF, 20% proteinase inhibitor cocktail] and incubated at 4°C for 30 min, followed by centrifugation at 12,000 g for 7 min. Protein concentrations were determined by a BCA (bicinchoninic acid) protein assay kit (Pierce) according to the manufacturer's instructions. Then, 500 g of whole cell protein were adjusted to a volume of 1 ml of RIPA and were incubated with 4 g of TGF-␤ 1 antibody for 2 h at 4°C on a rotator. Then, 20 l of Sepharose A/G beads were added to the antibody-lysate solution, mixed, and incubated overnight on a rotator at 4°C. The beads were washed three times with RIPA buffer (1 ml/wash) and the tubes were kept on ice as much as possible. After the final wash, 40 l of 2ϫ Laemmli sample buffer were added to the beads, vortexed, and boiled for 5 min. The tubes were allowed to cool and then were centrifuged to settle the beads. The supernatant, which contained the immunoprecipitated TGF-␤ 1, was load into a 15% gel and subject to SDS-PAGE.
Immunofluorescence. LLC-PK 1 cells grown on 18-mm coverslips were treated with the appropriate treatment for 48 h. The cells were fixed with 4% paraformaldehyde for 20 min. The fixed cells were then permeabilized for 20 min in 0.2% (vol/vol) Triton X-100, 100 mM glycine in PBS. Cells were washed three times in PBS and then blocked in 0.2% BSA/PBS for 1 h. The cells were then incubated a monoclonal mouse anti-claudin-4 (Zymed Laboratories) in 0.2% (wt/ vol) BSA/PBS for 1 h and Alexa 488-conjugated anti-mouse IgG antibody in 0.2% (wt/vol) BSA/PBS per well for 1 h. To stain the nuclei, cells were incubated with DAPI for 5 min. The whole process was carried out at room temperature. Coverslips were then mounted using the anti-quenching agent (Dako). The immunofluorescence was analyzed using a Zeiss Axioplan II epifluorescent microscope attached to a digital camera. Pixel intensity analysis of the immunofluorescent images using ImageJ was performed as previously described (1) . Briefly, pixel intensity was analyzed in five regions of interest (ROIs) in each image. Pixel intensity at cell junctions and in the cytoplasm was measured. These values were then averaged across the five ROIs and then converted to ratio of mean junctional intensities to mean cytoplasmic intensities.
Preparation of Triton X-100-soluble and -insoluble fractions for TJ protein analysis. This method has been adapted and modified from Yoo et al. (38) . LLC-PK 1 cells grown on a six-well tissue culture plate were washed twice with ice-cold PBS and then scraped in a Triton X-100 lysis buffer (1% Triton X-100, 20 mM Tris·HCl, 50 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, 50 mM NaF, 20 mM sodium pyrophosphate, 1 g/ml pepstatin, 0.5 g/ml leupeptin, 1.9 g/ml aprotinin) and incubated at 4°C for 30 min, followed by centrifugation at 12,000 g for 7 min. The resulting supernatant was considered the Triton X-100/detergent-soluble fraction. The remaining pellet was resuspended in SDS solubilization buffer (1% SDS, 20 mM Tris·HCl, 50 mM NaCl, 5 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, 50 mM NaF, 20 mM sodium pyrophosphate, 1 g/ml pepstatin, 0.5 g/ml leupeptin, 1.9 g/ml aprotinin) and briefly sonicated. After sonication, the suspension was incubated at 4°C for 30 min, followed by centrifugation at 12,000 g for 7 min. The supernatant was considered the Triton X-100/detergent-insoluble fraction. Protein concentrations were determined by a BCA protein assay kit (Pierce) according to the manufacturer's instructions and an equal amount of protein was analyzed.
Preparation of whole extracts for phosphorylated and whole cell ERK1/2 and Smad proteins analysis. Following the appropriate treatment, LLC-PK1 cells grown on a six-well tissue culture plate were washed twice with ice-cold PBS and then scraped in RIPA buffer [90% RIPA buffer (Sigma), 10% of 1 mM Na3VO4, 1% 1 mM PMSF, 20% proteinase inhibitor cocktail] and incubated at 4°C for 30 min, followed by centrifugation at 12,000 g for 7 min. The resulting supernatant was stored in aliquots at Ϫ20°C until required for immunoblotting. Protein concentrations were determined by a BCA protein assay kit (Pierce) according to the manufacturer's instructions and equal amounts were analyzed.
SDS-PAGE and Western blotting. Equal amounts of cell extracts were electrophoresed on SDS-polyacrylamide gels and proteins were transferred to nitrocellulose membrane. To ensure equal loading, membranes were stained with Ponceau-S. Membranes were blocked with 5% (wt/vol) milk proteins/Tris-buffered saline and incubated overnight at 4°C with the primary antibody: rabbit anti-claudin-1, mouse anti-claudin-4, rabbit anti-phospho-ERK1/2, rabbit anti-ERK1/2, rabbit anti-phospho-Smad 2, rabbit anti-Smad 2, rabbit anti-phospho-Smad 3, rabbit anti-Smad 3, or rabbit anti-Smad 7. Bound antibody was detected with appropriate secondary antibodies and enhanced chemiluminescence.
TGF-␤ 1 Smad-responsive reporter gene assay. Transient transfection and reporter gene analysis using LLC-PK1 cells were performed as follows. Briefly, 50% confluent LLC-PK1 cells were changed to serum-free medium for 12 h before addition of plasmids and the mixed lipofection agent FuGENE 6 (Roche Diagnostics) at a ratio of 1 g of plasmid, 3 l of transfection agent. After 10-h incubation, the cells were treated as described. One microgram of the plasmid pRL-CMV Renilla was used to control for transfection efficiency, together with 1 g Smad 3 reporter plasmid (a gift from Dr. Roel Goldschmeding). Following lysis of the cells in reporter lysis buffer (Promega, Southampton, UK), firefly and Renilla luciferase content was quantified using the Dual-Glo assay (Promega).
Statistical analysis. Statistical analyses were performed using the statistical program GraphPad Prism 4.0. (GraphPad, San Diego, CA). Data were analyzed by one-way ANOVA and multiple comparisons between different treatments were made using the Bonferoni posttest. Alternatively, the paired Student's t-test was used to test for statistical significance between control and a treatment group. Results were expressed as means Ϯ SE. A probability of 0.05 or less was deemed statistically significant between different treatments (#P Ͻ 0.05, ##P Ͻ 0.01, and ###P Ͻ 0.001) or time-matched control where indicated (*P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001).
RESULTS

Neutralization of TGF-␤ 1 reduced the CsA-and CsA/SRLinduced increase in TER in LLC-PK 1 monolayers.
Cotreatment of LLC-PK 1 cells with 30 g/ml of nAb TGF-␤ 1 significantly reduced but did not completely prevent the CsA-induced increase in TER that was observed when cells were treated with CsA (4.2 M) alone for 24 and 48 h (Fig. 1A) . This was achieved when nAb TGF-␤ 1 was added 1 h before the treatment with CsA but not with addition after 24-h CsA treatment (data not shown). Cotreatment of the LLC-PK 1 cells with 30 g/ml nAb TGF-␤ 1 also significantly reduced but did not completely prevent the CsA/SRL-induced increase in TER that was observed when cells were treated with 4.2 M CsA/1 M SRL alone for 48 h (Fig. 1B) . Again, this was only achieved when nAb TGF-␤ 1 was added 1 h before the treatment with CsA/SRL and not with addition after 24-h CsA/SRL treatment (data not shown).
CsA and CsA/SRL cotreatment induced TGF-␤ 1 gene and protein expression in LLC-PK 1 cells. RT-PCR experiments demonstrated that treatment of LLC-PK 1 cells with 4.2 M
CsA resulted in a threefold significant increase in TGF-␤ 1 mRNA at 24 h. Cotreatment of LLC-PK 1 cells with 4.2 M CsA plus 1 M SRL also resulted in a significant increase in TGF-␤ 1 mRNA at 24 h, which was greater than with CsA treatment alone (Fig. 2Ai) . This result was supported by immunoprecipitation studies of TGF-␤ 1 protein in LLC-PK 1 whole cell lysates after 4.2 M CsA, 1 M SRL, or CsA/SRL cotreatment that showed an increasing trend in protein expression levels at 48 h of treatment (Fig. 2Aii) .
TGF-␤ 1 treatment increased TER and neutralization of TGF-␤ 1 reduced the TGF-␤ 1 -induced increase in TER in
LLC-PK 1 monolayers. Treatment with 5 ng/ml TGF-␤ 1 decreased the ion paracellular permeability of LLC-PK 1 cell monolayers, which was detected as an increase in TER at 24 and 48 h (⌬TER: 22.7 and 73.8 ⍀·cm 2 , respectively; Fig.  2B ). Cotreatment of the LLC-PK 1 cells with 30 g/ml nAb TGF-␤ 1 significantly reduced and almost completely prevented the TGF-␤ 1 -induced (5 ng/ml) increase in TER that was observed when cells were treated with TGF-␤ 1 alone for 24 and 48 h (Fig. 2B ). This was only achieved when nAb TGF-␤ 1 was added 1 h before the treatment with CsA and not with addition after 24-h TGF-␤ 1 treatment (data not shown).
TGF-␤ 1 treatment increased the expression of the TJ proteins, claudin-1 and claudin-4, in LLC-PK 1 cells.
Claudin-1 and -4 were shown to be normally distributed in control LLC-PK 1 cells (Fig. 3, A and B) . No disruptions of the cell monolayer or gaps between cells were observed in any treatment group. Following 48-h treatment with 5 ng/ml TGF-␤ 1 , the fluorescent signal for claudin-1 and -4 appeared to be more concentrated at the cell periphery compared with control cells (Fig. 3, A and B) . A pixel intensity analysis of the immunofluorescent images indicated that there was a statistically significant increase in claudin-1 at the junctions (Fig. 3C) . A similar trend was seen for claudin-4 but this did not reach statistical significance. Western blot analysis of whole cell lysates showed that 5-ng/ml TGF-␤ 1 treatment significantly Results are expressed as the change in TER (⌬TER) compared with timematched control filters and are given as means Ϯ SE of 3 independent experiments, each performed in duplicate. ANOVA and multiple comparisons between different treatments were made using the Bonferoni posttest. Alternatively, the paired Student's t-test was used to test for statistical significance between different treatment groups. A probability of 0.05 or less was deemed statistically significant between different treatments (##P Ͻ 0.01 and ###P Ͻ 0.001) or time-matched control where indicated (**P Ͻ 0.01 and ***P Ͻ 0.001).
increased the total cell claudin-1 expression at 24 h (Fig. 4A ). An increasing trend was observed in the expression of claudin-4 ( Fig. 4B ) after TGF-␤ 1 treatment compared with control cells; however, this did not reach statistical significance due to large variability. GAPDH expression was used as sample loading control (Fig. 4C) . (Fig. 5A) . Cotreatment of the LLC-PK 1 cells with 10 M SD208 plus 4.2 M CsA/1 M SRL also significantly reduced but did not completely prevent the CsA/SRL-induced increase in TER that was observed when cells were treated with CsA/ SRL alone for 24 and 48 h (Fig. 5B) . Cotreatment of the LLC-PK 1 cells with 10 M SD208 plus 5 ng/ml TGF-␤ 1 completely prevented the TGF-␤ 1 -induced increase in TER that was observed when cells were treated with TGF-␤ 1 alone for 24 and 48 h (Fig. 5C) . The results to this point clearly indicated an involvement of TGF-␤ 1 in the CsA-and CsA/ SRL-mediated increase in TER. We next decided to investigate the possible signaling mechanisms involved in this process. Because of these results with lack of evidence for Smad 2/3 phosphorylation or activation of Smad reporter gene construct with CsA, SRL, or the CsA/SRL combination, we next investigated possible dose-response effects of added TGF-␤ 1 on Smad 2 phosphorylation in LLC-PK 1 cells. Western blot analysis of whole cell lysates showed that addition of 0.25 and 0.5 ng/ml TGF-␤ 1 was not able to stimulate the phosphorylation of Smad 2 after 24-h treatment (Fig. 6D) . Only concentrations higher than 0.5 ng/ml TGF-␤ 1 were able to stimulate the phosphorylation of Smad 2 at 24 h (Fig. 6D) .
Inhibition of TGF
We next decided to investigate whether expression of the inhibitory Smad 7 by CsA or CsA/SRL could be the cause of lack of activation of Smad 2/3. The levels of the inhibitory Smad 7 were not altered by either by 4.2-M CsA, 4.2-M CsA/1-M SRL, or 5-ng/ml TGF-␤ 1 treatment for 24 h (Fig.  6E) . With no evidence for Smad 2/3 phosphorylation after CsA or CsA/SRL, we next decided to investigate the possible role of ERK1/2 in the TGF-␤ 1 effect in barrier function.
Implication of ERK1/2 signaling pathway in the TGF-␤ 1 -induced increase in TER in LLC-PK 1 monolayers. Treatment of LLC-PK 1 cells with 5 ng/ml TGF-␤ 1 resulted in significant activation of ERK1/2 signaling at 24 and 48 h (Fig. 7A) . The MEK inhibitor U0126 (10 M) reduced basal activation of ERK1/2 and also prevented the TGF-␤ 1 -induced activation of Whole cell lysates were then made using RIPA lysis buffer and were subject to immunoprecipitation of TGF-␤1. Expression of TGF-␤1 was detected by Western blot as described in MATERIALS AND METHODS. B: LLC-PK1 cells were grown on Costar Transwell filters for 4 days. Cells were then pretreated for 1 h with 30 g/ml nAb TGF-␤1 before the treatment with 5 ng/ml TGF-␤1 up to 48 h. Results are expressed as ⌬TER compared with time-matched control filters and are given as means Ϯ SE of 3 independent experiments, each performed in duplicate. ANOVA and multiple comparisons between different treatments were made using the Bonferoni posttest. Alternatively, the paired Student's t-test was used to test for statistical significance between different treatment groups. A probability of 0.05 or less was deemed statistically significant between different treatments (#P Ͻ 0.05 and ##P Ͻ 0.01) or time-matched control where indicated (**P Ͻ 0.01).
ERK1/2 at 24 and 48 h (Fig. 7A ). This clearly indicates that TGF-␤ 1 can activate the ERK1/2 signaling pathway in LLC-PK 1 cells and that in this context the ERK1/2 signaling pathway is downstream of the TGF-␤ 1 receptor. We next tested whether inhibition of ERK1/2 would affect TGF-␤ 1 -mediated increases in TER. Cotreatment of LLC-PK 1 cells with the MEK inhibitor U0126 (10 M) plus 5 ng/ml TGF-␤ 1 significantly reduced the TGF-␤ 1 -induced increase in TER, which was observed when cells were treated with TGF-␤ 1 alone for 24 and 48 h (Fig. 7B) .
Inhibition of ERK1/2 signaling pathway reduced the TGF-␤ 1 -induced modulation of TJ protein claudin-1 in LLC-PK 1 cells. Western blot analysis showed that 5-ng/ml TGF-␤ 1 treatment caused an increase in claudin-1 localization in the insoluble fraction after 48-h treatment (Fig. 7C) . A similar trend was observed in claudin-4 distribution (Fig. 7C) ; however, this did not reach statistical significance due to large variability. U0126 reduced the TGF-␤ 1 -induced increase of claudin-1 in the insoluble fraction (Fig. 7C, right) . However, MEK inhibition with U0126 did not have a similar effect on claudin-4 but in contrast to claudin-1, a trend was observed for increased localization of claudin-4 in the insoluble fraction after combined TGF-␤ 1 and U0126 (Fig. 7C, right) . Coomassie brilliant blue staining was used as sample loading control. Because inhibition of ERK1/2 signaling prevented the TGFmediated increase in TER and claudin expression, we next decided to test whether inhibition of ERK1/2 would affect the TGF-␤ 1 -induced phosphorylation of Smad 2.
Inhibition of ERK1/2 signaling pathway did not prevent TGF-␤ 1 -induced phosphorylation of Smad 2 in LLC-PK 1 cells.
Cotreatment of LLC-PK 1 cells with 10 M MEK inhibitor U0126 plus 5 ng/ml TGF-␤ 1 did not prevent the TGF-␤ 1 -induced increase in Smad 2 phosphorylation, which was observed when cells were treated with TGF-␤ 1 alone for 48 h (Fig. 8A) . No Smad 2 phosphorylation (upper band indicated with arrow at 48 h in Fig. 8A ) was detected with either CsA or CsA/SRL alone or in the presence of U0126. Because blockage of the TGF-␤ 1 receptor kinase activity with SD208 showed inhibition of the TGF-␤ 1 -mediated increase in TER and claudin-1 localization, we decided to check whether SD208 would have an affect on the TGF-␤ 1 activation of ERK1/2 phosphorylation.
Inhibition of ERK1/2 signaling pathway reduced the CsA and CsA/SRL upregulation of the TGF-␤ 1 gene in LLC-PK 1 cells.
To test the hypothesis that CsA and CsA/SRL may also activate ERK1/2 upstream of the TGF-␤ 1 receptor and increase the expression of the TGF-␤ 1 gene, we investigated the effects of 10 M MEK inhibitor U0126 on the CsA and CsA/SRL induction of the TGF-␤ 1 gene (Fig. 8C) . Our results clearly show that inhibition of ERK1/2 prevented the CsA-and CsA/ SRL-induced upregulation of the TGF-␤ 1 gene. This clearly indicates that the ERK1/2 signaling pathway is also upstream of the TGF-␤ 1 receptor following treatment with CsA and CsA/SRL. (Fig. 8B ).
Inhibition of TGF-␤ 1 receptor II kinase activity did not prevent the
DISCUSSION
Our data provide strong evidence that TGF-␤ 1 is a key player not only in the CsA but also in the combined CsA/SRL- Fig. 3 . Effect of TGF-␤1 treatment on distribution of claudin-1 and claudin-4 and cell monolayer integrity in LLC-PK1 cells. LLC-PK1 cells were grown on coverslips in 12-well plates and on day 4 postseeding were treated either with VC or with 5 ng/ml TGF-␤1 for 48 h. A: claudin-1 was visualized using a polyclonal rabbit anti-claudin-1 antibody and an anti-rabbit FITC-conjugated secondary antibody. B: cells were stained for claudin-4 using a monoclonal anti-claudin-4 antibody and an anti-mouse FITC-conjugated secondary antibody. The immunofluorescence was analyzed using a Zeiss epifluorescent microscope. Magnification ϫ630; scale bars are shown. Images are representative of at least 3 independent experiments. C: pixel intensity analysis of the immunofluorescent images was performed as described in MATERIALS AND METHODS. Ratio of mean junctional intensities to mean cytoplasmic intensities across the 5 regions of interest (ROIs) is shown in the graph. ANOVA and multiple comparisons between different treatments were made using the Bonferoni posttest. A probability of 0.05 or less was deemed statistically significant (**P Ͻ 0.05) compared with time-matched controls.
induced enhancement of barrier function in LLC-PK 1 cells. Controversy about the protective role of SRL in nephropathy may be related to differences in alterations in levels of TGF-␤ 1 in different cell systems. Our data indicate that the CsA-and CsA/SRL-induced increase in TER is mediated, at least in part, by TGF-␤ 1 via ERK1/2 and not via a SMAD signaling pathway.
The CsA-and CsA/SRL-induced increases in TER could be reduced by the neutralizing antibody of TGF-␤ 1 . Neutralizing TGF-␤ 1 antibodies treatment in CsA-treated rats and mice has been shown to significantly reduce TGF-␤, collagen, and fibronectin mRNA levels (16, 21, 26) . Using a model of heart transplantation in rats receiving CsA treatment, Khanna et al. (22) Previous work in our laboratory demonstrated that CsA increased TGF-␤ levels in both renal canine distal tubular cells (11) and human proximal tubular cells (33) . Here, we demonstrated that treatment of LLC-PK 1 cells with CsA induced an upregulation of TGF-␤ 1 gene expression. Moreover, we observed that the combined treatment of CsA and SRL far from Results are expressed as ⌬TER compared with time-matched control filters and are given as means Ϯ SE of 3 independent experiments, each performed in duplicate. ANOVA was carried out and multiple comparisons between control and treatment groups were made using the Bonferroni posttest. A probability of 0.05 or less was deemed statistically significant (*P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001) compared with other treatment groups. Fig. 4 . Effect of TGF-␤1 treatment on claudin-1 and claudin-4 expression in whole cell LLC-PK1 cellular lysates. LLC-PK1 cells were grown on 6-well plates. When confluent they were exposed to VC or 5 ng/ml TGF-␤1 for 24 or 48 h. Whole cell lysates were then made using RIPA lysis buffer. Expression of claudin-1 (A) and claudin-4 (B) was detected by Western blot as described in MATERIALS AND METHODS. The nitrocellulose was then stripped of the antibody and expression of GAPDH (C) was identified using a monoclonal antibody and an anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody. Results are expressed as means Ϯ SE of 3 independent experiments. Relative change in protein band density of blots is shown. Paired Student's t-test was used to test for statistical significance between control and a treatment group. A probability of 0.05 or less was deemed statistically significant (*P Ͻ 0.05) compared with time-matched controls.
preventing the gene expression of TGF-␤ actually increased it. Furthermore, we provided evidence that treatment with CsA and CsA/SRL activates the ERK1/2 signaling pathway and that this is involved in the upregulation of the TGF-␤ 1 gene expression.
Our results support evidence that SRL augments the nephrotoxicity of CsA. Swinford et al. (35) reported that SRL increased TGF-␤ mRNA expression in immortalized rat proximal renal tubular cells. They observed an additive effect when CsA and SRL were used in combination. Shihab et al. (31) also demonstrated that SRL increased TGF-␤ 1 expression and potentiated chronic CsA nephrotoxicity in a rat model. They showed that SRL alone did not alter renal function and structure but it potentiated the nephrotoxic actions of CsA when used in combination with low-dose CsA and resulted in significant changes similar to high-dose CsA. A recent study in a model of nephrotoxicity in rats showed that TGF-␤ 1 was markedly enhanced in rats treated with CsA/SRL combination (27) . Our present results are fully compatible with these in vivo studies but provide a more mechanistic approach indicating alteration in barrier function involving increased claudin expression mediated by TGF-␤ 1 .
Other studies, however, support the hypothesis that SRL can prevent renal dysfunction in models of CsA-induced nephropathy in rats (5) or in models of unilateral urethral obstruction kidneys where SRL ameliorated renal dysfunction and decreased TGF-␤ levels (7, 37) .
TGF-␤ has been shown before to enhance the barrier function of intestinal epithelial cell monolayers and to promote intestinal epithelial restitution (3, 9, 29) . Our previous studies in MDCK cells demonstrated that the CsA-induced modulation of paracellular permeability was mediated by an increase in TGF-␤ and ERK1/2 activation that regulates TJ protein expression (11) . In the present studies in LLC-PK 1 cells, TGF-␤ 1 treatment increased the localization of claudin-1 and -4 in insoluble fractions of cell lysates. Claudin-1 and -4 are related to the tightness of the epithelium in renal epithelial cells. Therefore, these results suggest that TGF-␤ 1 is capable of modulating the kidney epithelial barrier via alterations in TJ protein expression and this correlates with the observed TGF- , D) , phospho-Smad 3 (B), or Smad 7 (E) was detected by Western blot as described in MATERIALS AND METHODS. The nitrocellulose was then stripped of the antibody and probed with an antibody against whole cell Smad 2, Smad 3, or ␤-actin, respectively. Representative blots from 1 of 3 separate experiments are shown. C: confluent LLC-PK1 cells were treated with 4.2 M CsA, 1 M SRL, CsA/SRL, or 5 ng/ml TGF-␤1 for 24 h. Smad activation was measured using a Smad-responsive luciferase construct. Smad-responsive luciferase values were normalized to a control renilla luciferase construct. Each column represents means Ϯ SE of 3 independent experiments performed in duplicate. Paired Student's t-test was used to test for statistical significance between control and treatment groups. A probability of 0.05 or less was deemed statistically significant (**P Ͻ 0.01) compared with control group. ␤ 1 -induced increase in TER. These results with TGF-␤ 1 on claudin-1 and -4 are very consistent with the earlier findings we reported on the effects of CsA and CsA/SRL on claudin-1 and -4 (28) .
To address the possible intracellular signaling mechanisms involved, we decided to analyze the direct implication of the TGF-␤ 1 receptor activation. We inhibited the ability of TGF-␤ receptor II to phosphorylate TGF-␤ receptor I by the chemical compound SD208. The CsA-, CsA/SRL-, and TGF-␤ 1 -induced effect on TER was blocked by the use of SD208, indicating that phosphorylation and subsequent activation of the TGF-␤ receptor I played an essential role in the modulation of the permeability barrier function. However, we could find no evidence that CsA or CsA/SRL induced activation of the canonical Smad 2/3 pathway in the LLC-PK 1 cells. We were, however, able to demonstrate that addition 5 ng/ml of TGF-␤ 1 induced phosphorylation of both Smad 2 and 3 in the LLC-PK 1 cells. The TGF-␤ 1 canonical pathway was further analyzed using a Smad promoter luciferase construct. Only TGF-␤ 1 treatment and not CsA or CsA/SRL was able to induce an approximately threefold increase in the activity of the Smad promoter, confirming the results obtained by Western blot that CsA and CsA/SRL did not activate the Smad signaling pathway.
However, in different renal cells namely rat mesengial cells, there is evidence that CsA treatment can induce activation of the Smad signaling pathway (2). However, these authors demonstrated that the CsA-mediated Smad activation was not calcineurin dependent but was actually triggered by reactive oxygen species. It may be that mesangial cells are more primed to generate reactive oxygen species compared with proximal epithelial cells. Two studies reported Smad activation after CsA treatment in mouse kidneys (25) and allograft kidneys in rats (12) . However, these in vivo studies did not identify the cells involved in the Smad activation.
One possible explanation for the lack of Smad activation in the present studies in LLC-PK 1 cells is that after CsA or CsA/SRL treatment Smad 7 (which competes with Smad 2/3 for the binding to the activated receptor) may have been upregulated by CsA and CsA/SRL. However, we observed that Smad 7 levels were very similar in all treatment groups. Another possible explanation is that the CsA-and CsA/SRLinduced TGF-␤ 1 might not be sufficient to achieve the level required for Smad 2/3 activation. Here, we demonstrated that the phosphorylation of Smad 2 in LLC-PK 1 monolayers treated with TGF-␤ 1 does not occur at TGF-␤ 1 concentrations lower than 750 pg/ml. We attempted to accurately quantify the amount of TGF-␤ 1 released by the LLC-PK 1 cells with the different treatments using a number of commercially available ELISA kits with different antibodies. We found that even after concentrating samples the levels of TGF-␤ 1 protein were below the levels of the lowest standard provided and were below 50 pg/ml. Samples from the human proximal tubular epithelial cell line, HK-2, were run as positive controls and it was possible to quantify the amount of TGF-␤ 1 released from the HK-2 cells. We previously showed in HK-2 cells that the amount of TGF-␤ 1 stimulated by CsA was in the region of 250 pg/ml (34) . Therefore, it is highly likely that in the present studies with LLC-PK 1 cells, the amount of TGF-␤ 1 released following CsA or CsA/SRL did not reach the level (750 pg/ml) required to activate Smad signaling in these cells as shown in the present studies . It may be conceivable that the sensitivity of the Smad 2/3 phosphorylation assay was not sufficient to detect activation with the very low levels of TGF-␤ 1 detected after CsA and CsA/SRL. However, this is unlikely to be an explanation as the sensitivity of the TGF-␤ 1 gene reported assay is much greater and no evidence of stimulation of the Smad reporter gene was detected after treatment with CsA and CsA/SRL.
In terms of alternative possible signaling mechanisms, we turned our attention to ERK1/2 signaling following earlier findings (28) . In the present studies, we showed that treatment of LLC-PK 1 confluent monolayers with TGF-␤ 1 also activated ERK1/2 at 24 and 48 h and this activation was prevented by the MEK inhibitor U0126. Moreover, use of the ERK1/2 inhibitor blocked TGF-␤ 1 -induced enhancement of the barrier function and prevented the increase in claudin-1 localization in the membrane fraction. In the case of the claudin-4 expression, however, a trend for an increase in the localization of this protein in the membrane after the inhibition of ERK1/2 was observed. These results correspond to the same effects that inhibition of ERK1/2 had on these two TJ proteins after CsA and CsA/SRL treatment as we previously reported (28) . These findings strengthen our hypothesis that TGF-␤ 1 may mediate, at least in part, the CsA-and CsA/SRL-induced enhancement of the barrier function in LLC-PK 1 monolayers via the ERK1/2 signaling pathway. In this process, claudin-1 seems to play a more important role than claudin-4 in regulating the tightness of the paracellular pathway in LLC-PK 1 cells. Moreover, we provide evidence that inhibition of ERK1/2 signaling pathway maintained activation of Smad 2 induced by 5 ng/ml TGF-␤ 1 while preventing the TGF-␤ 1 -induced increase in TER. This strongly suggests an ERK1/2-dependent and Smad-independent mechanism. This possible mechanism is presented diagrammatically in Fig. 9 . It is well-established that the TGF-␤ 1 family signaling pathways involve both Smad-dependent and Smad-independent pathways as reviewed by Derynck and Zhang (8) . There is increasing interest in the roles of these different pathways in biological processes. It has been reported that TGF-␤ 1 activates Erk MAP kinase signaling through direct phosphorylation of ShcA (24) . It has also been suggested that inhibition of the ERK1/2 pathway may be a potential thera- Fig. 7 . Effect of ERK1/2 inhibition on TGF-␤1-induced ERK1/2 phosphorylation, TGF-␤1-induced increase on TER, and claudin-1 and claudin-4 protein localization in LLC-PK1 cells. A, C: confluent LLC-PK1 cells were treated with VC or 5 ng/ml TGF-␤1 or pretreated with U0126 before the treatment with TGF-␤1 for 24 or 48 h. A: whole cell lysates were then made using RIPA lysis buffer. Expression of phospho-ERK1/2 was detected by Western blot as described in MATERIALS AND METHODS. The nitrocellulose was then stripped of the antibody and expression of whole cell ERK1/2 was identified using a polyclonal antibody and an anti-rabbit HRP-conjugated secondary antibody. Results were expressed as means Ϯ SE of 5 experiments. Ratio phospho-ERK/whole cell ERK band density of blots is shown in the graphs. ANOVA and multiple comparisons between different treatments were made using the Bonferoni posttest. A probability of 0.05 or less was deemed statistically significant (*P Ͻ 0.05, **P Ͻ 0.01, and ***P Ͻ 0.001) between different treatments or time-matched controls where indicated. B: LLC-PK1 cells were grown on filters for 4 days. Cells were then pretreated for 1 h with 10 M U0126 before treatment with 5 ng/ml TGF-␤1. Results are expressed as ⌬TER compared with time-matched control cells and are given as means Ϯ SE of 5 independent experiments, each performed in duplicate. ANOVA was carried out and multiple comparisons between control and treatment groups were made using the Bonferroni posttest. A probability of 0.05 or less was deemed statistically significant (**P Ͻ 0.01 and ***P Ͻ 0.001) compared with other treatment groups. C: Triton-X-soluble (s) and Triton-X-insoluble (i) cell fractions were made using membrane separation buffer. Expression of claudin-1 and anti-claudin-4 was detected by Western blot as described in MATERIALS AND METHODS. Coomassie staining of the gel was used as a loading control. A representative blot from 1 of 3 separate experiments is shown. Each column represents means Ϯ SE of 3 independent experiments for claudin-1 and -4, respectively. ANOVA was carried out and multiple comparisons between different treatment groups were made using the Bonferroni posttest. A probability of 0.05 or less was deemed statistically significant between different treatments (*P Ͻ 0.05).
peutic target in disease processes involving the noncanonical TGF-␤ 1 signaling pathway (13) . Other authors reported the implication of the ERK1/2 signaling pathway in TGF-␤ 1 -induced modulation of paracellular permeability in other systems including intestinal and murine mammary epithelial cells (14, 36) .
An intriguing observation in our experiments was the finding that TGF-␤ 1 receptor blockage could not prevent the phosphorylation of ERK1/2 but however prevented the CsA-and CsA/ SRL-induced increase in TER. This observation led us to speculate that ERK1/2 might also be upstream of TGF-␤ 1 in CsA and CsA/SRL effects on transepithelial permeability. This is also consistent with our previous findings in HK-2 cells that the TGF-␤ 1 induction by CsA in these cells could be prevented by blocking ERK1/2 with UO126 (34).
Overall, our results in LLC-PK 1 cells clearly demonstrate a role for TGF-␤ 1 not only in the CsA-but also in the CsA/SRLmediated alterations in TER and claudin-1 expression. Furthermore, they indicate that signaling through ERK1/2 is involved in this process. In this cell model, no evidence was found to indicate a requirement for Smad signaling to mediate the TGF-␤ 1 -induced alterations in barrier function in renal proximal tubular cells. A schema summarizing the possible mechanisms involved including upregulation of claudin-1 and claudin-4 is presented in Fig. 9 . The insights provided in this study may be useful in developing therapeutic strategies to ameliorate CsA-and CsA/SRL-induced nephrotoxicity while maintaining immunosuppressive activity. Expression of phospho-Smad 2 (A) and phospho-ERK1/2 (B) was detected by Western blot as described in MATERIALS AND METHODS. The nitrocellulose was then stripped of the antibody and expression of whole cell Smad 2 (A) and ERK1/2 (B) was identified using a polyclonal antibody and an anti-rabbit HRP-conjugated secondary antibody. Note: Phospho-Smad 2 corresponds to the top band and is indicated by an arrow. The bottom band corresponds to whole cell Smad 2 after stripping of the immunoblot. B: ratio phospho-ERK/ whole cell ERK band density of blots from 5 independent experiments is shown. ANOVA and multiple comparisons between different treatments were made using the Bonferoni posttest. A probability of 0.05 or less was deemed statistically significant (**P Ͻ 0.01 and ***P Ͻ 0.001) compared with controls. Paired Student's t-test was used to test for statistical significance between treatment group and treatment with SD208. C: LLC-PK1 cells were pretreated for 1 h with 10 M U0126 before the treatment with 4.2 M CsA, 4.2 M CsA/1 M SRL, or VC for 48 h. TGF-␤1 gene expression was detected by quantitative PCR. Each column represents means Ϯ SE of 3 independent experiments performed in duplicate. Paired Student's t-test was used to test for statistical significance between control and treatment groups. A probability of 0.05 or less was deemed statistically significant (*/#P Ͻ 0.05, **/##P Ͻ 0.005, ***/###P Ͻ 0.001). Fig. 9 . Proposed mechanisms by which TGF-␤1 mediates CsA-and CsA/SRLinduced modulation of the paracellular pathway. CsA treatment alone or in combination with SRL activates phosphorylation of ERK1/2, which may induce increases in TGF-␤1 expression levels. TGF-␤1 levels induced after CsA and CsA/SRL may be not sufficient to activate the Smad canonical pathway but however may trigger other TGF-␤1 receptor activations, such as ERK1/2 signaling pathway. Activation of ERK1/2 signaling pathway induces increases in claudin-1 expression and localization in the tight junction (TJ), which lowers the ion permeability and is detected as increases in TER. CsA and CsA/SRL treatment may also increase the expression/activity of other molecules that could activate ERK1/2 and claudin-1. 
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